BPH treatment evaluation for your institution.
Product information, evaluation support, and partnership pathways — designed to help your team assess whether a non-thermal, non-implant BPH treatment fits your clinical portfolio.
INSTITUTION FIT
Is your institution ready to evaluate?
Institutions best positioned to evaluate share a common profile: established urology service, experience with minimally invasive techniques, and a clinical team open to differentiated approaches.
General hospitals
Urology departments expanding their BPH minimally invasive portfolio.
Day surgery centers
Facilities seeking efficiency with day-case urology procedures.
Specialty urology clinics
Clinics building differentiated BPH care capabilities.
Experienced MIST teams
Already doing MIST, evaluating non-thermal options.
THE CASE
Why institutions evaluate this pathway
A non-thermal, non-implant approach creates clarity at every stage — from the pre-treatment conversation to the compliance review.
Start an evaluationClearer clinical communication
Not thermal ablation, not a permanent implant — physicians can explain the approach to patients in plain terms, supporting differentiated positioning and informed consent conversations.
Focused evaluation discussions
Internal assessment narrows to four clear questions: target patient population, differentiation, team training, and documentation completeness. Nexusuro provides structured support for each.
Verifiable compliance foundation
NMPA registration and ISO 13485-certified manufacturing provide a clear starting point for institutional compliance review — no gaps to investigate, no opaque supply chain.
EVALUATION SCOPE
What your team will assess
Every institution's evaluation follows a structured path — from clinical indication to documentation review.
| Evaluation question | What Nexusuro provides |
|---|---|
| Target patient population | Structured clinical indication materials with patient selection criteria — focus on small-volume prostate (≤40 mL) and post-TURP bladder neck contracture (strong recommendation) |
| Differentiation from current alternatives | Comparison briefs covering thermal, implant, and medical management benchmarks |
| Training and early clinical support | Structured onboarding pathway with clinical specialist guidance through initial cases |
| Regulatory and compliance documentation | NMPA certificate, ISO 13485 documentation, and product technical file |
EVALUATION SUPPORT
What you receive during evaluation
Product pathway and indication overview
How the technology fits into existing BPH treatment workflows.
Technical and differentiation briefs
How the non-thermal, non-implant approach compares to alternatives.
Compliance documentation package
NMPA registration and ISO 13485 manufacturing certification.
Early-stage coordination
Dedicated point of contact for evaluation-phase questions.
THE PROCESS
How partnership begins
Initial review
Review product pathway and applicable clinical scenarios with your department.
Internal assessment
Evaluate fit against clinical goals, patient population, and existing treatment portfolio.
Submit inquiry
Request formal evaluation materials through the hospital inquiry channel.
Formal B2B engagement
Product documentation, training plans, and commercial terms — via structured process.
The Nexusuro Prostate Dilation System holds NMPA registration. The manufacturer operates ISO 13485-certified facilities. For formal procurement, documentation review, and commercial terms, inquiries proceed through the hospital partnership channel.